FORM 5

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

20549

I OININ J	OTHER STATES SECONATIVES AND
	Washington, D.C. 2
Check this box if no longer subject to Section 16. Form 4 or Form 5	
obligations may continue. See Instruction 1(b).	ANNUAL STATEMENT OF CHA
maduction I(b).	

OMB APPROVAL

	OIVID AFFROVAL				
ANNUAL STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP	OMB Number: Estimated average burd	3235-0362 den			
	hours per response:	1.0			

Form 3 Holdings Reported.

Form 4 Transactions Reported.

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* KAZIMI A J	2. Issuer Name and Ticker or Trading Symbol CUMBERLAND PHARMACEUTICALS INC [CPIX]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director X 10% Owner						
(Last) (First) (Middle)		X	Officer (give title below)		Other (specify below)			
2525 WEST END AVE. SUITE 950	3. Statement for Issuer's Fiscal Year Ended (Month/Day/Year) 12/31/2020		Chairman and CEO					
	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Indiv	ridual or Joint/Group	Filing	(Check Applicable			
(Street) NASHVILLE TN 37203		Line) X	Form filed by One	•	9			
(City) (State) (Zip)			Person					

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities A Of (D) (Instr. 3		A) or Disposed	5. Amount of Securities Beneficially	6. Ownership Form: Direct	7. Nature of Indirect Beneficial
				Amount	(A) or (D)	Price	Owned at end of Issuer's Fiscal Year (Instr. 3 and 4)	(D) or Indirect (I) (Instr. 4)	Ownership (Instr. 4)
Common Stock	07/08/2020		L4	15(1)(2)	A	\$3.33	5,791,322	D	
Common Stock	07/09/2020		L4	15(1)	A	\$3.27	5,791,337	D	
Common Stock	07/10/2020		L4	15(1)	A	\$3.24	5,791,352	D	
Common Stock	07/13/2020		L4	15(1)	A	\$3.23	5,791,367	D	
Common Stock	07/14/2020		L4	15(1)	A	\$3.26	5,791,382	D	
Common Stock	07/15/2020		L4	15(1)	A	\$3.31	5,791,397	D	
Common Stock	07/16/2020		L4	15(1)	A	\$3.34	5,791,412	D	
Common Stock	07/17/2020		L4	15(1)	A	\$3.33	5,791,427	D	
Common Stock	07/20/2020		L4	15 ⁽¹⁾	A	\$3.52	5,791,442	D	
Common Stock	07/21/2020		L4	15 ⁽¹⁾	A	\$3.29	5,791,457	D	
Common Stock	07/22/2020		L4	15(1)	A	\$3.22	5,791,472	D	
Common Stock	07/23/2020		L4	15 ⁽¹⁾	A	\$3.31	5,791,487	D	
Common Stock	07/24/2020		L4	15(1)	A	\$3.31	5,791,502	D	
Common Stock	07/27/2020		L4	15(1)	A	\$3.28	5,791,517	D	
Common Stock	07/28/2020		L4	15(1)	A	\$3.26	5,791,532	D	
Common Stock	07/29/2020		L4	15(1)	A	\$3.21	5,791,547	D	
Common Stock	07/30/2020		L4	15(1)	A	\$3.22	5,791,562	D	
Common Stock	07/31/2020		L4	15 ⁽¹⁾	A	\$3.36	5,791,577	D	
Common Stock	08/03/2020		L4	15(1)	A	\$3.43	5,791,592	D	
Common Stock	08/04/2020		L4	15(1)	A	\$3.41	5,791,607	D	
Common Stock	08/05/2020		L4	15(1)	A	\$3.44	5,791,622	D	
Common Stock	08/06/2020		L4	15(1)	A	\$3.39	5,791,637	D	
Common Stock	08/07/2020		L4	15(1)	A	\$3.43	5,791,652	D	
Common Stock	08/10/2020		L4	15(1)	A	\$3.43	5,791,667	D	
Common Stock	08/11/2020		L4	15(1)	A	\$3.43	5,791,682	D	
Common Stock	08/12/2020		L4	15(1)	A	\$3.48	5,791,697	D	
Common Stock	08/13/2020		L4	15(1)	A	\$3.48	5,791,712	D	
Common Stock	08/14/2020		L4	15(1)	A	\$3.41	5,791,727	D	
Common Stock	08/17/2020		L4	15 ⁽¹⁾	A	\$3.35	5,791,742	D	

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																			
1. Title of Security (Instr. 3)		2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year	3. Transact Code (In					Securiti Benefici	5. Amount of Securities Beneficially Owned at end of		6. Ownership Form: Direct (D) or		7. Nature of Indirect Beneficial Ownership					
			(MOIIIII/Day/Teal	9		Amount	(A) or (D)	Price	Issuer's Fiscal Year (Instr. 3 and 4)		Indirect (I) (Instr. 4)		(Instr. 4)						
Common Stock			08/18/2020		L4		15(1)	A	\$3.43	5,79	5,791,757		5,791,757		5,791,757 D		D		
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																			
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Transaction Code (Instr. 8)	of	6. Date Exercisable and Expiration Date (Month/Day/Year)		An Se Un De Se	Fitle and tount of curities derlying rivative curity (Instr. and 4)	8. Price of Derivative Security (Instr. 5)	9. Numbe derivativ Securitie Beneficia Owned Following Reported Transact (Instr. 4)	e ally g ion(s)	10. Ownersl Form: Direct (E or Indire (I) (Instr.	hip o E O) C ect (I	11. Nature of Indirect Beneficial Ownership (Instr. 4)				

Date Exercisable

Expiration Date

Title

Explanation of Responses:

- 1. The purchase reported in this Form 5 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2020.
- 2. Filing 3 of 6.

Remarks:

A.J. Kazimi by /s/ Michael Bonner as attorney-in-fact

Amount or Number of Shares

02/05/2021

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

(A) (D)